Skip to main content
. 2023 Oct 17;33(12):1155–1171. doi: 10.1093/glycob/cwad085

Fig. 4.

Fig. 4

The sialyltransferase inhibitor P-SiaFNEtoc effectively blocks sialylation in prostate cancer cells and reduces colony formation. A, B) Inhibition of sialylation in PC3 and CWR22RV1 cells using P-SiaFNEtoc detected using pan-specific Lectenz lectin flow cytometry (Saunders et al. 2023). Cells were treated with a range of concentrations of P-SiaFNEtoc inhibitor from 0.03 μM to 4 μM for 72 h. The intensities were normalized to a DMSO control. C, D) Detection of sialylated N-glycans in prostate cancer cells by immunocytochemistry using SNA and MAL-I lectins. PC3 and CWR22RV1 cells treated with 2 μM P-SiaFNEtoc for 72 h have reduced levels of SNA and MAL-I binding indicating a reduction in both α2-6 and α2-3 linked sialylation in these cells. Scale bar is 20 μm. E) WST-1 cell proliferation assays show treatment of PC3 or CWR22RV1 cells with 2 μM P-SiaFNEtoc hours does not significantly alter cell proliferation over 72 h. F) Treatment of PC3 or CWR22RV1 cells with 2 μM P-SiaFNEtoc significantly reduced colony formation over 14 days. Representative data from 3 biological repeats is shown.